Case Type: Mergers & Acquisitions

Watford Holdings Ltd. (WTRE) relating to proposed acquisition of the company by Arch Capital Group Ltd. Under the terms of the acquisition agreement, WTRE’s shareholders will receive $31.10 in cash per share.

Oaktree Acquisition Corp. (OAC) relating to its merger with Hims, Inc. Under the terms of the agreement, Oaktree shareholders will retain ownership of only 12% of the combined company.

South Mountain Merger Corp. (SMMC) relating to its merger with Billtrust. Under the terms of the agreement, SMMC shareholders will own only 17% of the combined company.

Churchill Capital Corp II (CCX) relating to its merger agreement with Skillsoft. Under the terms of the agreement, Churchill II’s shareholders are expected to own approximately 65% of the combined company.

Third Point Reinsurance Ltd. (TPRE) relating to its merger with Sirius International Insurance Group (“Sirius”).Under the terms of the agreement, Sirius shareholders will be issued (i)$9.50 in cash per share or (ii) 0.743 shares of TPRE and one CVR per share or (iii) a variable mix of cash and TPRE shares.

Perceptron, Inc. (PRCP) relating to its sale to Atlas Copco North America, LLC. Under the terms of the agreement, Perceptron shareholders will receive $7.00 in cash per share.

Cleveland BioLabs, Inc. (CBLI) relating to its proposed merger with Cytocom, Inc. Under the terms of the agreement, BioLabs shareholders will retain only 39% control of the combined company.

Bridge Bancorp, Inc. (BDGE) relating to its combination with Dime Community Bancshares, Inc. Under the terms of the agreement, Dime shareholders will receive 0.6480 shares of Bridge common stock for each share of Dime common stock owned.

Concho Resources, Inc. (CXO) relating to its proposed acquisition by ConocoPhillips. Under the terms of the agreement, Concho shareholders will receive 1.46 shares of ConocoPhillips for each share of Concho they own.

BioSpecifics Technologies Corp. (BSTC) relating to its proposed acquisition by Endo International PLC. Under the terms of the agreement, BioSpecifics shareholders will receive $88.50 per share in cash.